Who Owns Glaukos Company?

Who owns Glaukos Corporation?

Glaukos Corporation is a public med-tech company based in Aliso Viejo, California. It was founded in 1998 and built around less invasive glaucoma care. Ownership now sits with public shareholders, insiders, and the board.

There is no parent company or single controlling owner. That makes governance, voting power, and insider stakes the key things to watch, along with [Glaukos Balanced Scorecard](/products/glaukos-balanced-scorecard).

Glaukos ownership today is public and diffuse: Glaukos Corporation is listed on the NYSE under GKOS, so public shareholders own it, not a parent firm or private sponsor. Founder Thomas W. Burns remains the most visible individual holder and strategic face, while Glaukos institutional investors own most of the stock.

Public ownership now

Who owns Glaukos today? Its shares trade on the NYSE, so ownership sits with Glaukos stockholders in the public market. No single owner appears to control the company.

Founder role

Who founded Glaukos Company? Thomas W. Burns is the founder most closely tied to the brand. He remains the key individual in Glaukos founder ownership and public identity.

Institutional base

Glaukos institutional ownership is the main ownership block in practice. Large fund managers such as Vanguard, BlackRock, and State Street are typical top holders in a company with this profile.

Insiders and institutions

Glaukos insiders and institutional ownership point to a founder influenced but widely held public med-tech company. Insiders hold low-single-digit ownership, while institutions do most of the economic work.

Shareholder trust

The Glaukos ownership structure supports credibility because it depends on reporting, board oversight, and execution. That matters when customers and investors ask who is the largest shareholder of Glaukos.

Early control

Glaukos ownership details show a typical path from founder-led startup to public company. Early control centered on the founder, but today the Glaukos stock ownership breakdown is market driven.

For a wider market view, see the Competitors Landscape of Glaukos. That context helps explain why Glaukos company major shareholders matter, since public med-tech firms often trade on trust, pipeline execution, and disclosure quality.

Glaukos shareholder profile

Glaukos Corporation investor ownership is best read as founder influenced, institutionally owned, and widely dispersed. The company is publicly traded, and that makes the shareholder mix more important than any single sponsor.

• NYSE ticker GKOS confirms public listing
• Founder Thomas W. Burns remains visible
• Institutional funds hold most shares
• No controlling owner is evident

Glaukos SWOT Analysis

• Organized to Save Time on Analysis
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Glaukos Corporation changed from a founder-led medical device story into a public company when it went public in 2015. That shift changed Glaukos ownership from private control to a tracked Glaukos stock ownership breakdown with quarterly reporting, proxy filings, and more scrutiny from Glaukos institutional investors and public Glaukos stockholders.

That change matters because public ownership adds audited financials, SEC filings, and visible Glaukos shareholder information. It also shifts the question from who founded Glaukos Company to who owns most of Glaukos stock today, with Glaukos insiders and institutional ownership now shaping the stock more than any private backer once did. For a close read on the business model behind that ownership story, see Revenue Streams & Business Model of Glaukos.

How public ownership changed Glaukos

Glaukos ownership moved from founder control to a public-market mix after the 2015 IPO. That made Glaukos Corporation investor ownership easier to track and compare.

• Glaukos stockholders gained quarterly disclosure.
• Hospitals saw clearer governance signals.
• Analysts could test growth assumptions.
• Investors could judge capital use faster.

Glaukos company major shareholders now matter because they influence voting power, board oversight, and market trust. In practice, Glaukos company investor relations must answer to Glaukos top shareholders, including Glaukos institutional ownership and named insiders, while the market keeps asking is Glaukos publicly traded and who is the largest shareholder of Glaukos.

Glaukos Ansoff Matrix

• Structured to Support Better Decisions
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Glaukos Corporation's board is centered on founder-led oversight, with Thomas W. Burns shaping strategy and investor perception. Glaukos is publicly traded and its Glaukos ownership structure appears closer to one-share-one-vote than to founder veto control, so board alignment and Glaukos institutional ownership matter a lot.

For investors asking who owns Glaukos, the key point is that Glaukos stockholders do not face a dual-class setup that locks in control for one holder. That means Glaukos Corporation shareholders, especially Glaukos major shareholders and Glaukos institutional investors, can matter through voting power, while the board still steers the day-to-day guardrails. For a quick background, see the Brief History of Glaukos.

Who Holds Real Influence Over Glaukos Corporation

Real control is spread across founder leadership, the board, and Glaukos institutional investors. No hidden parent company appears to sit above the public float, so Glaukos shareholder information and proxy votes matter.

• Thomas W. Burns shapes strategy.
• Board committees still check management.
• Funds influence votes and pay.
• One-share-one-vote limits hidden control.

Glaukos Balanced Scorecard

• Clean, Modern, and Easy to Present
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Glaukos ownership has stayed stable in recent years: it remains publicly traded, has no controlling parent, and is still anchored by founder continuity plus broad institutional support. That mix usually signals steady Glaukos Corporation investor ownership rather than a takeover-driven story.

For investors asking who owns Glaukos, the key point is simple: Glaukos stockholders are split across founders, insiders, and institutions, so the Glaukos stock ownership breakdown tends to support accountability rather than private control. That structure can help brand credibility because surgeons and clinicians usually trust a company more when the science is backed by public reporting and a visible governance process, as seen in the broader story behind the Marketing Strategy of Glaukos.

Founder-led credibility

who founded Glaukos Company matters because founder continuity often signals long product cycles. That can support trust when the business sells specialized eye-care technology.

Public-market discipline

is Glaukos publicly traded is important for credibility. Public reporting helps investors and clinicians track execution, cash use, and governance.

Institutional support

Glaukos institutional ownership usually supports stability and trading depth. It also adds pressure for clear guidance and consistent delivery.

Ownership risk

The main risk is not control change, but short-term market pressure. That can push strategy toward near-term growth instead of longer clinical goals.

Glaukos VRIO Analysis

• Designed for Fast Business Analysis
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔